AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the ...

AstraZeneca and Oracle team up on AI, aiming to speed up clinical trials and improve patient care pathways, with the first ...

Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify ...

AstraZeneca and Oracle Health and Life Sciences today announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and ...

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant ...

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and ...

AstraZeneca agrees a $40m upfront deal with insitro to use AI in drug discovery for MASH and cardiomyopathies. Read more.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp up their collaboration on developing cancer treatments.

AstraZeneca (AZN) inks up to $1.5B AI drug discovery deal with insitro to target MASH and cardiomyopathies. Read more here.

AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended ...